Clinical Trials on Non-Myeloid Malignancies

Total 25164 results

Amgen

Completed

Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa

Anemia | Non-Myeloid Malignancies
Amgen

Completed

Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy

Cancer | Non-Myeloid Malignancies
Amgen

Completed

Chemotherapy Related Anemia

Anemia | Non-Myeloid Malignancies
Amgen

Completed

A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

Anemia | Non-Myeloid Malignancies
Amgen

Completed

Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

Anemia | Non-Myeloid Malignancies
Amgen

Completed

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Anemia | Non-Myeloid Malignancies
Amgen

Completed

Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies

Cancer | Anemia | Non-Myeloid Malignancies
Pharmacosmos A/S

Completed

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Non-myeloid Malignancies | Chemotherapy Induced Anaemia

India
Gilead Sciences

Completed

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Myeloid Malignancies

United States, Australia, United Kingdom
Southwest Hospital, China

Unknown

A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies

Myeloid Malignancies

China
Sichuan University

Recruiting

Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies

Myeloid Malignancies

China
Southwest Hospital, China

Unknown

A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies

Myeloid Malignancies

China
Amgen

Completed

Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy

Cancer | Anemia | Non-Myeloid Malignancies
Cristina Gasparetto
Agilent Technologies, Inc.

Active, not recruiting

Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT (NK-DCI)

Lymphoid Malignancies | Myeloid Malignancies

United States
M.D. Anderson Cancer Center

Active, not recruiting

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

Myeloid Malignancies | Lymphodepleting Chemotherapy

United States
Charite University, Berlin, Germany
University of Leipzig

Unknown

Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells

Acute Myeloid Leukemias | Advanced Hematological Malignancies | Indication for Allogeneic Stem Cell Transplantation | no HLA-identical Donor Available

Germany
Amgen

Terminated

Darbepoetin Alfa and Anemia of Cancer

Neoplasms | Carcinoma | Cancer | Anemia | Non-Myeloid Malignancies | Anemia of Cancer
Catherine Bollard
Johns Hopkins University; Children's National Research Institute

Recruiting

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE)

Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS

United States
AbbVie
Genentech, Inc.

Completed

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Japan
ExCellThera inc.
Memorial Sloan Kettering Cancer Center

Recruiting

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

Cord Blood Transplant | High Risk Myeloid Malignancies

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia

Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia

Japan
Caribou Biosciences, Inc.

Enrolling by invitation

Long-Term Follow-up Study (LTFS)

Lymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Hematologic Malignancy | Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Acute Myeloid Leukemia | Relapsed Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin's Lymphoma

United States
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
Gruppo Italiano Trapianto di Midollo Osseo

Completed

Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies (GITMO-PHYLOS)

Myeloid Malignancies

Italy
Novartis Pharmaceuticals

Active, not recruiting

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Belgium, Italy, Korea, Republic of, Hong Kong, Israel, Finland, Spain, Japan, United States
Gilead Sciences

Completed

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Lymphoma, Non-Hodgkin (NHL)

United States
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Completed

Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies (UCAML)

Myeloid Hematological Malignancies

United States
Novartis Pharmaceuticals

Completed

Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer

NON-breast HER2+ Malignancies

United States, Italy, Korea, Republic of, Japan
Pfizer

Terminated

A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors

Advanced Non-Hematologic Malignancies

United States, United Kingdom
University of Illinois at Chicago

Completed

Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies (IM-TMI)

Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Acute Leukemia | Lymphoblastic Leukemia | Non Hodgkins Lymphoma

United States
Pfizer

Completed

CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies

Advanced Non-Hematologic Malignancies

United Kingdom
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Novartis... and other collaborators

Terminated

Trial of PTK787/ZK 222584 Plus Paclitaxel

Metastatic Non-hematologic Malignancies

United States
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies

Advanced Non-hematologic Malignancies

United States, Canada
Forma Therapeutics, Inc.

Completed

Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

Acute Myeloid Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
AbbVie
Genentech, Inc.; Amgen

Terminated

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

Acute Myeloid Leukemia | Non-Hodgkin's Lymphoma | Diffuse Large B-cell Lymphoma

United States, Australia, Germany
Amgen

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | AML | Myelodysplastic Syndrome | MDS | Non-Hodgkins Lymphoma | NHL

United States, Australia, Italy, France, Greece, Japan
Astellas Pharma Global Development, Inc.

Terminated

A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

Non-hematologic Malignancies | Pharmacokinetics of ASP9853

United States
Institut de Recherches Internationales Servier

Recruiting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Myelodysplastic Syndromes | Relapsed or Refractory Acute Myeloid Leukemia (AML) | Untreated AML | Other IDH1-mutated Positive Hematologic Malignancies

United States, France
Erasca, Inc.

Withdrawn

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies (HERKULES-4)

Acute Myeloid Leukemia

United States
St. Jude Children's Research Hospital
Ohio State University; Arog Pharmaceuticals, Inc.

Completed

Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

Acute Myeloid Leukemia

United States
Amgen

Completed

Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia

Leukemia | Myeloid Leukemia | Cancer | Hematologic Malignancies

United States
Hospices Civils de Lyon

Unknown

Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy (EPREX/LAM-ALLO)

Acute Myeloid Leukemia | Anemia

France
Amgen

Terminated

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

Advanced Non-Central Nervous System (CNS) Malignancies

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Acute Myeloid Leukemia | Multiple Myeloma | Non-hodgkin's Lymphoma

China
Gilead Sciences

Terminated

Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults (Japanese AML)

Acute Myeloid Leukemia | Hematologic Malignancy

Japan
AvenCell Europe GmbH
Allucent (NL) BV

Recruiting

Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

Germany, Netherlands
Nanjing Chia-tai Tianqing Pharmaceutical

Recruiting

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

Relapsed/Refractory Acute Myeloid Leukemia (AML)

China
Prelude Therapeutics

Completed

A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Non Hodgkin Lymphoma

United States
AstraZeneca

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | High Risk Myelodysplastic Syndrome | Small Lymphocytic Lymphoma | B-cell Non-Hodgkin Lymphoma | Richter's Syndrome | T-cell Non-Hodgkin Lymphoma | Relapsed or Refractory...

United Kingdom, Germany, Netherlands

Clinical Trials on Non-Myeloid Malignancies

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations